Mer­ck KGaA inks ADC dis­cov­ery deal with AI tech­bio worth up to $1.4B in mile­stones

Mer­ck KGaA is part­ner­ing with AI tech­bio Caris Dis­cov­ery to iden­ti­fy and de­vel­op new an­ti­body-drug con­ju­gates in a move that could ex­pand the Ger­man com­pa­ny’s on­col­o­gy port­fo­lio.

Irv­ing, TX-based Caris will get an undis­closed up­front pay­ment and re­search fund­ing and is al­so el­i­gi­ble for up to $1.4 bil­lion in mile­stones and tiered roy­al­ties on sales, per a Thurs­day re­lease. Mer­ck KGaA will take re­spon­si­bil­i­ty for pre­clin­i­cal re­search through com­mer­cial­iza­tion for AD­Cs against up to 15 se­lect­ed tar­gets, for which it will get glob­al li­cens­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.